
|Videos|June 7, 2015
Drug Shows 10-Month Survival Improvement in Sarcoma
Author(s)William D. Tap, MD
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
Advertisement
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma
2
Autogene Cevumeran & The Future of Personalized Cancer Vaccines
3
New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial
4
The Synergy of Early Detection and KRAS Inhibition in Pancreatic Cancer
5


























































